Nuntius Therapeutics has entered into a collaboration agreement with Taiho Pharmaceutical Co., Ltd. to develop novel mRNA cancer immunotherapies using Nuntius’ cell-specific peptide dendrimer- and lipid-based nanocarriers. The collaboration aims to improve treatments for cancer patients and utilize Nuntius’ high-performing mRNA nanocarriers.